冬凌草甲素对骨肉瘤细胞MG63增殖和凋亡的影响及其可能机制

doi:10.20047/j.issn1673-7210.2022.34.04

Abstract
Figure/Table
References (25)
Related Citation (11)

Download: PDF (2071 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of oridonin (ORI) on proliferation and apoptosis of human osteosarcoma MG63 cells and the possible mechanism. Methods The experimental groups were treated with different concentrations of ORI (10, 20, 30, 40 and 50 μmol/L), and the control group was treated with the same amount of DMSO. Crystal violet staining was used to investigate the proliferation of MG63 cells. Western blot was used to detect the proteins of proliferation, apoptosis, and β-catenin. Flow cytometry was used to assess apoptosis of MG63 cells. T-cell factor/lymphoid enhancing factor(TCF4/ LEF) luciferase reporter plasmid was used to detect the effect on Wnt signal transduction. SqRT-PCR was used to analyze the expression of β-catenin in MG63 cells. Results There was no significant difference in crystal violet staining and quantitization between 10 μmol/L ORI and control group (P＞0.05), but 20 to 50 μmol/L ORI group was lower than control group, and the difference was statistically significant (P＜0.05). 10 μmol/L ORI group was higher than 20-50 μmol/L ORI group, 20 μmol/L ORI was higher than 30-50 μmol/L ORI, 30 μmol/L ORI was higher than 40 and 50 μmol/L ORI, 40 μmol/L ORI was higher than 50 μmol/L ORI, and the differences were statistically significant (P＜0.05). The expression level of PCNA in experimental group was lower than that in control group, and the difference was statistically significant (P＜0.05). Expression levels of caspase-3, Cleaved caspase-3, and Bad were higher in the experimental group than in the control group, with statistical significance (P＜0.05). The expression level of Bcl-2 in all experimental groups was higher than that in control group, 20 and 30 μmol/L were lower than 10 μmol/L, 30 μmol/L was lower than 20 μmol/L, the differences were statistically significant (P＜0.05). The expression of β-catenin in experimental group was lower than that in control group, 20 and 30 μmol/LORI was lower than 10 μmol/LORI, 30 μmol/LORI was lower than 20 μmol/L LORI, the differences were statistically significant (P＜0.05). Compared with the control group, the apoptotic cells increased significantly in the experimental group, and decreased at 30 μmol/L, but the cell necrosis increased significantly. The transcriptional activity of TCF4/LEF reporter plasmids in all experimental groups was lower than that in control group, 20 and 30 μmol/L ORI were lower than 10 μmol/L ORI, 30 μmol/L ORI was lower than 20 μmol/L ORI, the differences were statistically significant (P＜0.05). The expression of β-catenin in experimental group was lower than that in control group, 20 and 30 μmol/L ORI was lower than 10 μmol/L ORI, 30 μmol/L ORI was lower than 20 μmol/L ORI, the difference was statistically significant (P＜0.05). Conclusion ORI inhibited proliferation and induced apoptosis in MG63 cells, which might be partly related to the inhibition of Wnt signal in this cancer cell line.

Key words： Oridonin Osteosarcoma Wnt Apoptotic promotion

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZOU Xiang ZHAO Zhengming HU Huaping HUANG Bin CHEN Guanghua DING Hong

Cite this article:

ZOU Xiang ZHAO Zhengming HU Huaping HUANG Bin CHEN Guanghua DING Hong. Effect on proliferation and apoptosis of Oridonin on MG63 osteosarcoma cells and its possible mechanism[J]. 中国医药导报, 2022, 19(34): 17-22.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.34.04 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I34/17

[1] Rat R，Van BA. Pathogenesis and Current Treatment of Osteosarcoma：Perspectives for Future Therapies [J]. J Clin Med，2021，10（6）：1182.
[2] Pru ZD，Yus JT. Recent Insights into Therapy Resistance in Osteosarcoma [J]. Cancers （Basel），2020，13（1）：83.
[3] Bar M，Muk M，Rah A，et al. Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma [J]. Biosensors （Basel），2021，11（2）：55.
[4] He H，Jiang H，Chen Y，et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity [J]. Nat Commun，2018，9（1）：2550.
[5] Wang S，Yu L，Yang H，et al. Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an Aβ1-42-Induced Mouse Model of Alzheimer’s Disease [J]. PLoS One，2016，11（3）：e0151397.
[6] Yuan Z，Ouyang P，Gu K，et al. The antibacterial mechanism of oridonin against methicillin-resistant Staphylococcus aureus （MRSA） [J]. Pharm Biol，2019，57（1）：710716.
[7] Wang Z，Zhao T，Zhang S，et al. The Wnt signaling pathway in tumorigenesis，pharmacological targets，and drug development for cancer therapy [J]. Biomark Res，2021，9（1）：68.
[8] Sha A，Mir R，Gal S. Epigenetic Regulation of the Wnt/ β-Catenin Signaling Pathway in Cancer [J]. Front Genet，2021，12：681053.
[9] Yu F，Yu C，Li F，et al. Wnt/β-catenin signaling in cancers and targeted therapies [J]. Signal Transduct Target Ther，2021， 6（1）：307.
[10] Meh S，Hin S，Cha V. The Emerging Mechanisms of Wnt Secretion and Signaling in Development [J]. Front Cell Dev Biol，2021，9：714746.
[11] Guo J，Zhang T，Dou D. Knockdown of HOXB8 inhibits tumor growth and metastasis by the inactivation of Wnt/ β-catenin signaling pathway in osteosarcoma [J]. Eur J Pharmacol，2019，854：22-27.
[12] Nom M，Rai N，LeeYC，et al. Tegavivint and the β-Catenin/ ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma [J]. J Natl Cancer Inst，2019，111（11）：1216-1227.
[13] Dan G，Mor S，Réd F，et al. New Insights about the Wnt/ β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment：A Promising Target to Develop Therapeutic Strategies? [J]. Int J Mol Sci，2019，20（15）：3751.
[14] Xia S，Zhang X，Li C，et al. Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling [J]. Saudi Pharm J，2017，25（4）：638-643.
[15] Par H，Jeo YJ，Han NK，et al. Oridonin Enhances Radiation-Induced Cell Death by Promoting DNA Damage in Non-Small Cell Lung Cancer Cells [J]. Int J Mol Sci，2018， 19（8）：2378.
[16] Zhao X，Zhang Q，Wang Y，et al. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling [J]. Ann Transl Med，2021，9（13）：1084.
[17] Lu Y，Sun Y，Zhu J，et al. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway [J]. Cell Death Dis，2018，9（1）：15.
[18] Wang XH，Zhang SF，Bao JT，et al. Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins [J]. Tumour Biol，2017，39（6）：1010428317701638.
[19] Liu J，Xiao Q，Xiao J，et al. Wnt/β-catenin signalling：function，biological mechanisms，and therapeutic opportunities [J]. Signal Transduct Target Ther，2022，7（1）：3.
[20] Mar E，Pér M，V?觟g O，et al. WNT/β-Catenin Pathway in Soft Tissue Sarcomas：New Therapeutic Opportunities? [J] Cancers，2021，13（21）：5521.
[21] Del M，Mir S，Ash M，et al. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression： An Emphasis on Molecular Pathways [J]. J Hepatocell Carcinoma，2021，8：1415-1444.
[22] Tru S，Can D，Del I，et al. Inhibition of Wnt-β-Catenin Signaling by ICRT14 Drug Depends of Post-Transcriptional Regulation by HOTAIR in Human Cervical Cancer HeLa Cells [J]. Front Oncol，2021，11：729228.
[23] Ji Y，Lv J，Sun D，et al. Therapeutic strategies targeting Wnt/ β-catenin signaling for colorectal cancer（Review） [J]. Int J Mol Med，2022，49（1）：1.
[24] Veg OA，Luc CMJ，Ara HF，et al. Wnt/β-Catenin Signaling Activates Expression of the Bone-Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types [J]. J Cell Biochem，2017，118（11）：3662-3674.
[25] He J，Ling L，Liu Z，et al. Functional interplay between long non-coding RNAs and the Wnt signaling cascade in osteosarcoma [J]. Cancer Cell Int，2021，21（1）：313.